Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-01-26
2009-12-22
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387900, C530S388100, C530S388150, C530S388220, C424S130100, C424S133100, C424S135100, C424S136100, C424S139100, C435S007100, C435S070210
Reexamination Certificate
active
07635757
ABSTRACT:
The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
REFERENCES:
patent: 5698520 (1997-12-01), Honjo et al.
patent: 6803192 (2004-10-01), Chen
patent: 6808710 (2004-10-01), Wood et al.
patent: 2002/0055139 (2002-05-01), Holtzman et al.
patent: 2006/0153841 (2006-07-01), Freeman et al.
patent: 2007/0122378 (2007-05-01), Freeman et al.
patent: 1074617 (2000-07-01), None
patent: WO 95/03408 (1995-02-01), None
patent: WO-01/14556 (2001-03-01), None
patent: WO-01/14557 (2001-03-01), None
patent: WO-01/39722 (2001-06-01), None
patent: WO-02/078731 (2002-10-01), None
Bendayan M., J. Histochem. Cytochem., 1995, 43: 881-886.
Lederman et al., Molecular Immunology, 1991, 28: 1171-1181.
Carninci et al., Methods Enzymol., 303: 19-44, May 15, 1999.
NCBI Accession No. Q3U472.
Sequence alignment, 1 page.
Attwood, Teresa K., “The Babel of Bioinformatics,” Science 290(5491):471-473 (2000).
Coyle et al., “The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function,” Nature lmmonology, 2(3):203-209 (2001).
Dong et al., Genbank Acession No. AF177937Homo sapiensB7-H1 mRNA, complete cds (Jan. 19, 2000).
Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion,” Nature Medicine 5(12):1365-1369 (1999).
Freeman et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation,” Journal of Experimental Medicine, 192(7)1027-1034 (1998).
Henry et al., “Structure and evolution of the extended B7 family,” Immunology Today, 20(6):285-288 (1999).
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotechnology, 18(1):34-39 (2000).
Steadman's Medical Dictionary, 24th Edition, 1982 Williams & Wilkins, Baltimore, MD, USA, p. 42.
Voet et al., Biochemistry, vol. 1, 1990 John Wiley & Sons, pp. 126-128, 230.
Genbank Acession No. AA292201 zt50f01.r1 Soares ovary tumor NbHOTHomo sapienscDNA clone Image:725785 5′, mRNA sequence (Apr. 21, 1997).
Genbank Acession No. AA399416 zt50f01.s1 Soares ovary tumor NbHOTHomo sapienscDNA clone Image:725785 3′, mRNA sequence (Apr. 29, 1997).
Genbank Acession No. Q13410 Butyrophilin precursor (BT) (Nov. 1, 1997).
Agata et al., “Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes,” International Immunology 8(5):765-772 (1996).
Anderson, “Nucleic Acid Hybridizataion,” Bio Scientific Publishers (Springer): 1989, p. 82.
Bennett et al., “Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses,” The Journal of Immunology 17:711-718 (2003).
Blazar et al., “Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism,” The Journal of Immunology 171:1272-1277 (2003).
Code #'s 27-7975-01, 27-7609-01, 27-7610-01, 27-7856-01, 27-7857-01, or 27-7858-01 in Pharmacia Biotech “BioDirectory” 1997 catalog, p. 44, Pharmacia Biotech Inc., 800 Centennial Ave., Piscataway, New Jersey 08855-1327.
Ellis et al., “Interactions of CD80 and CD86 with CD28 and CTLA4,” J. Immunol 56:2700-2709 (1996).
Finger et al., “The human PD-1 gene complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors,” Gene 197:177-187 (1997).
Greenfield et al., “CD28/B7 costimulation: a review,” Critical Reviews in Immunology 18:389-418 (1998).
Greenwald et al., “The B7 Family Revisited,” Annu. Rev. Immunol., 23:515-548 (2005).
Greenwald et al., “Negative co-receptors on lymphocytes,” Cur. Opin. Immunol 14:391-396 (2002).
Honjo, Tasuku, “Seppuku and Autoimmunity,” Science 258:591-592 (1992).
Huang, Z., “Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis,” Pharmacology & Therapeutics 86(3):201-215 (2000).
lshida et al., “Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death,” The EMBO Journal 11(11):3887-3895 (1992).
lwai et al., “Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade,” PNAS 99(19):12293-12297 (2002).
Ledbetter et al., “Agonistic activity of a CD40-specific single-chain Fv contructed from the variable regions of mAb G28-5,” Crit. Rev. lmmunol. 17:427-435 (1997).
Liang et al., “The right place at the right time: novel B7 family members regulate effector T cell responses,” Cur. Opin. lmmunol. 14:384-390 (2002).
Metzler et al., “Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28,” Nature Structural Biol 4:527-531 (1997).
Nishimura et al., “Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice,” Science 291(5502):319-22 (2001).
Nishimura et al., “Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 gene Encoding an ITM Motif-Carrying lmmunoreceptor,” Immunity 11:141-151 (1999).
Nishimura et al., “Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4 CD8) thymocytes,” International Immunology 8(5):773-780 (1996).
Nishimura et al., “Facilitation of β Selection and Modification of Positive Selection in the Tymus of PD-1-deficient Mice,” Journal of Experimental Medicine 191(5):891-897 (2000).
Nishimura et al., “Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses,” International Immunology 10(10):1563-1572 (1998).
Nishimura et al., “PD-1 Regulates Self-Tolerance to Prevent Tissue Destruction,” Journal of Investigative Dermatology 110(4):477, Abstract No. 25.
Nishimura et al., “PD-1 Regulates Self-Tolerance to Prevent Tissue Destruction,” Journal of Dermatological Science 16(1):S5, Abstract No. 0025.
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press: 1989, p. 9.47-9.57.
Shinohara et al., “Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1),” Genomics 23:704-706 (1994).
Thilenius et al., “Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants,” Eur. J. Immunol. 27-1108-1114 (1997).
Thompson et al., “The emerging role of CTLA-4 as an immune attenuator,” Immunity 7(4):445-450 (1997).
Vibhakar et al., “Activation-Induced Expression of Human Programmed Deth-I Gene in T-Lymphocytes,” Experimental Cell Research 232:25-28 (1997).
Vivier et al., “Immunoreceptor tyosin-based inhibition motifs,” Immunology Today 18:286-291 (1997).
Woronicz et al., “Death Genes in T Cells,” Current Topics Microbiol. lmmunol. 200:137-146 (1995).
Boussiotis Vassiliki
Chernova Tatyana
Freeman Gordon
Malenkovich Nelly
Dana-Farber Cancer Institute Inc.
Foley & Hoag LLP
Ouspenski Ilia
LandOfFree
B7-4 Antibodies and uses therefor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with B7-4 Antibodies and uses therefor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and B7-4 Antibodies and uses therefor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4087650